{"id":"338cf717-13d4-51a4-bac0-6ba1866095b9","stable_key":"220adaab-10d8-5c4e-a3f5-a48700ea794d:agmatine-sulfate-oral-tolerability","predicate":"associated_with","statement":"Three participants in the highest dose-escalation cohort reported diarrhea and mild nausea that resolved after stopping agmatine sulfate.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"90e095d5-dd4a-51e5-a39b-7abaedab8c95","mechanism_event_label":"Tolerability at one dose and duration cannot establish universal long-term safety.","subject":{"id":"ae2dddf4-ce04-57e3-8a06-7ed9fdc24554","slug":"agmatine-sulfate","display_name":"Agmatine Sulfate","entity_type_key":"small_molecule"},"object":{"id":"7258b7c2-786f-5223-9169-ea4f73d52c64","slug":"human-agmatine-sulfate-gi-tolerability","display_name":"Human agmatine-sulfate gastrointestinal tolerability","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"90e095d5-dd4a-51e5-a39b-7abaedab8c95","stable_key":"220adaab-10d8-5c4e-a3f5-a48700ea794d:agmatine-sulfate-oral-tolerability-event","event_type":"observed_relationship","label":"Tolerability at one dose and duration cannot establish universal long-term safety.","description":"Three participants in the highest dose-escalation cohort reported diarrhea and mild nausea that resolved after stopping agmatine sulfate.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"ae2dddf4-ce04-57e3-8a06-7ed9fdc24554","slug":"agmatine-sulfate","display_name":"Agmatine Sulfate","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"7258b7c2-786f-5223-9169-ea4f73d52c64","slug":"human-agmatine-sulfate-gi-tolerability","display_name":"Human agmatine-sulfate gastrointestinal tolerability","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"e2f83eb4-99ed-5050-87d3-3e4701d05c1a","slug":"agmatine","display_name":"Agmatine","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"3634af03-823b-584f-8e8e-e6ab6e3fbb60","slug":"sulfate","display_name":"Sulfate / SO4(2-)","entity_type_key":"ion"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Open-label regimens from 1.335 to 3.560 g/day for 10–21 days preceding the randomized trial.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"The source does not establish a safe maximum for all users or identify sulfate as the cause of the symptoms.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Agmatine Sulfate collection; species, compartment, exposure, co-substrates and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"agmatine-sulfate","display_name":"Agmatine Sulfate","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Tolerability at one dose and duration cannot establish universal long-term safety.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Safety and Efficacy of Dietary Agmatine Sulfate in Lumbar Disc-associated Radiculopathy. An Open-label, Dose-escalating Study Followed by a Randomized, Double-blind, Placebo-controlled Trial. · 2010 · https://pubmed.ncbi.nlm.nih.gov/20447305/ · DOI 10.1111/j.1526-4637.2010.00808.x","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"1c3d2cca-4a05-5cc3-b528-1c033a826bb3","evidence_kind":"source_excerpt","locator":"Lines 444-450","start_line":444,"end_line":450,"excerpt":"## agmatine-sulfate-oral-tolerability\nTolerability at one dose and duration cannot establish universal long-term safety.\nThree participants in the highest dose-escalation cohort reported diarrhea and mild nausea that resolved after stopping agmatine sulfate.\nModel: Open-label regimens from 1.335 to 3.560 g/day for 10–21 days preceding the randomized trial.\nLimitations: The source does not establish a safe maximum for all users or identify sulfate as the cause of the symptoms.\nEvidence access: Primary abstract\nSafety and Efficacy of Dietary Agmatine Sulfate in Lumbar Disc-associated Radiculopathy. An Open-label, Dose-escalating Study Followed by a Randomized, Double-blind, Placebo-controlled Trial. · 2010 · https://pubmed.ncbi.nlm.nih.gov/20447305/ · DOI 10.1111/j.1526-4637.2010.00808.x","model_system":"Open-label regimens from 1.335 to 3.560 g/day for 10–21 days preceding the randomized trial.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"e0426971-7d13-51c9-8354-6547b664f1cf","stable_key":"import-220adaab-10d8-5c4e-a3f5-a48700ea794d","title":"Agmatine Sulfate: transport, guanidino metabolism, ion channels and cross-nutrient mechanisms (2026-09-20)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"b55d70e22d07b80964f825770d92fdd1745221420ed8af8d94ca5182b9994509","revision_id":"fc7be029-20e0-5943-b74e-3b06ba694571","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}